Aim immunotech announces abstract from university of pittsburgh medical center accepted for presentation at the aacr 2022 annual meeting

Ocala, fla., march 09, 2022 (globe newswire) -- aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including covid-19, the disease caused by the sars-cov-2 virus — announced today that data from the ongoing phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing ampligen® (rintatolimod) was accepted for presentation at the american association for cancer research (aacr) annual meeting 2022, being held april 8-13, 2022, in new orleans, louisiana.
AIM Ratings Summary
AIM Quant Ranking